Kezar Life Sciences, Inc.
KZR
$6.24
$0.091.46%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -61.71M | -70.79M | -78.63M | -83.74M | -95.78M |
| Total Depreciation and Amortization | 980.00K | 1.01M | 1.03M | 1.04M | 1.06M |
| Total Amortization of Deferred Charges | 304.00K | 331.00K | 354.00K | 259.00K | 252.00K |
| Total Other Non-Cash Items | 8.25M | 8.28M | 9.70M | 9.53M | 11.72M |
| Change in Net Operating Assets | -4.46M | -3.14M | -986.00K | -1.30M | 6.38M |
| Cash from Operations | -56.64M | -64.30M | -68.54M | -74.21M | -76.37M |
| Capital Expenditure | -19.00K | -37.00K | -37.00K | -29.00K | -19.00K |
| Sale of Property, Plant, and Equipment | 9.00K | -- | -- | -- | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 64.61M | 72.98M | 73.80M | 80.46M | 84.58M |
| Cash from Investing | 64.60M | 72.94M | 73.76M | 80.43M | 84.56M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -3.91M | -2.61M | -1.30M | -- | -- |
| Issuance of Common Stock | 82.00K | 82.00K | 103.00K | 103.00K | 115.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -3.83M | -2.53M | -1.20M | 103.00K | 115.00K |
| Foreign Exchange rate Adjustments | -47.00K | -22.00K | -51.00K | -63.00K | 50.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4.08M | 6.09M | 3.97M | 6.26M | 8.36M |